生物通

使用主动脉内球囊泵与Impella 5.5辅助进行心脏移植的过渡研究

比较IABP与Impella 5.5桥接治疗心脏移植的临床特征和预后。单中心回顾性研究纳入2018年10月18日至2023年5月31日间的91例患者，其中54例使用IABP，37例使用Impella 5.5。Impella组基线特征相似，但MCS期间血管活性药物用量更少（p0.05），但MCS和ICU时间更长。术后并发症率 ...
生物通

Impella 5 + 患者使用比伐卢定联合双联抗血小板治疗的血液相容性相关 ...

为评估急性心肌梗死心源性休克（AMICS）患者使用 Impella 5 + 辅助、比伐卢定联合双联抗血小板治疗（DAPT）时血液相容性相关并发症，研究人员开展回顾性单中心队列研究。结果显示相关血栓和出血事件发生率低，该研究为 tMCS 抗凝方案提供参考。 在心血管疾病 ...
Business Wire

Abiomed Receives FDA PMA Approval for Impella 5.5 with SmartAssist, a Minimally Invasive ...

DANVERS, Mass.--(BUSINESS WIRE)--Abiomed’s (NASDAQ: ABMD) newest heart pump, the Impella 5.5 with SmartAssist, has received U.S. Food and Drug Administration (FDA) pre-market approval (PMA) for safety ...
Business Wire

Two Milestones Achieved Toward Small Bore Access with Impella

DANVERS, Mass.--(BUSINESS WIRE)--Abiomed (NASDAQ: ABMD) announces the achievement of two milestones in the development of small bore access for the Impella heart pump. The Impella ECP heart pump has ...
Nasdaq

Impella® SmartAssist Platform Launches at ESC, Designed to Further Improve Patient Outcomes

PARIS--(BUSINESS WIRE)-- Abiomed (NASDAQ: ABMD) announces today that the Impella CP ® with SmartAssist technology, which is designed to improve patient outcomes with advanced algorithms and simplified ...